By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Ablynx 

Technologiepark 4

Ghent  Zwijnaarde  9052  Belgium
Phone: 32-0-9-261-06-32 Fax: 32-0-9-261-06-28


SEARCH JOBS








Company News
Ablynx (ABLYF) Announces 2014 Full Year Results 2/26/2015 1:18:46 PM
Ablynx (ABLYF) Will Announce Its Full Year Results 2014 With Webcast 2/19/2015 8:30:10 AM
Ablynx (ABLYF) Successfully Opposes Patent Appeal Case By Domantis Limited (GlaxoSmithKline (GSK)) 1/22/2015 8:18:38 AM
Ablynx (ABLYF) Announces Warrant Exercise 1/21/2015 7:35:24 AM
Ablynx (ABLYF) To Present At The 33rd Annual J.P. Morgan Healthcare Conference 1/7/2015 10:09:15 AM
Ablynx (ABLYF) Opens Recruitment For First-In-Infant Phase 2a Study With Its Anti-Rsv Nanobody, ALX-0171 12/17/2014 7:23:45 AM
Additional Clinical Data From The Phase 2 Study With Ablynx (ABLYF)'s Anti-vWF Nanobody, Caplacizumab, Presented At The American Society of Hematology Annual Meeting 12/8/2014 8:17:33 AM
Ablynx (ABLYF) Demonstrates Bioequivalence Between Liquid And Lyophilised Formulations Of Its Anti-Vwf Nanobody, Caplacizumab 12/1/2014 10:14:27 AM
Ablynx (ABLYF) Demonstrates Bioequivalence Between Liquid And Lyophilised Formulations Of Its Anti-Vwf Nanobody, Caplacizumab 11/26/2014 2:17:50 PM
Ablynx (ABLYF) Appoints Johan Heylen As Chief Commercial Officer 11/18/2014 4:26:58 PM
12345678910...
//-->